The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.